Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia

Journal of Neurochemistry

Volumn 106, Issue 2, 2008, Pages 770-780

  Woo, Moon Sook ^a   Park, Jin Sun ^a   Choi, In Young ^b   Kimf, Won Ki ^b   Kim, Hee Sun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Matrix metallopro teinase 9; Matrix metalloproteinase 3; Microglia; Neuroinflammation; Signaling pathways

Indexed keywords

ACETYLCYSTEINE; DIPHENYLIODONIUM SALT; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERSTITIAL COLLAGENASE; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NEUTROPHIL COLLAGENASE; NITRIC OXIDE; PHORBOL 13 ACETATE 12 MYRISTATE; REACTIVE OXYGEN METABOLITE; STROMELYSIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; ENZYME INHIBITOR; NITRITE;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; ENZYME INHIBITION; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; ANIMAL; BRAIN CORTEX; CYTOLOGY; DRUG EFFECT; ENZYME ACTIVATION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; METHODOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CEREBRAL CORTEX; CYTOKINES; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MICE; MICROGLIA; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; TRANSFECTION;

EID: 51649102877     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05430.x     Document Type: Article

References (55)

1. Agrawal S. M., Lau L. and Yong V. W. (2007) MMPs in the central nervous system: where the good guys go bad. Semin. Cell Dev. Biol. 19, 42-51.
2. Aoshiba K., Yasuda K., Yasui S., Tamaoki J. and Nagai A. (2001) Serine proteases increase oxidative stress in lung cells. Am. J. Physiol Lung Cell Mol. Physiol. 281, L556-L564.
3. Block M. L. and Hong J. S. (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76, 77-98.
4. Block M. L., Zecca L. and Hong J. S. (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57-69.
5. Cauwe B., Van den Steen P. E. and Opdenakker G. (2007) The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matirx metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 42, 113-185.
6. Cocks T. M. and Moffatt J. D. (2000) Protease-activated receptors: sentries for inflammation? Trends Pharmacol. Sci. 21, 103-108.
7. Coughlin S. R. and Camerer E. (2003) PARticipation in inflammation. J. Clin. Invest. 111, 25-27.
8. Cunningham L. A., Wetzel M. and Rosenberg G. A. (2005) Multiple rolesfor MMPs and TIMPs in cerebral ischemia. Glia 50, 329-339.
9. Dzwonek J., Rylski M. and Kaczmarek L. (2004) Matrix metallopro-teinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett. 567, 129-135.
10. Gao H. M., Liu B., Zhang W. and Hong J. S. (2003) Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 17, 1954-1956.
11. Gasche Y., Soccal P. M., Kanemitsu M. and Copin J. C. (2006) Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front Biosci. 11, 1289-1301.
12. Gijbels K., Galardy R. E. and Steinman L. (1994) Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J. Clin. Invest. 94, 2177-2182.
13. Glezer I., Simard A. R. and Rivest S. (2007) Neuroprotective role of the innate immune system by microglia. Neuroscience 147, 867-883.
14. Goerge T., Barg A., Schnaeker E. M. et al. (2006) Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res. 66, 7766-7774.
15. 15N] nitrate in biological fluids. Ann. Biochem. 126, 131-138.
16. Gu Z., Kaul M., Yan B., Cui J., Strongin A., Smith J. W., Liddington R. C. and Lipton S. A. (2002) S-nitrosylation of matrix metallo-proteinases: signaling pathway to neuronal cell death. Science 297, 1186-1190.
17. Hammani K., Blakis A., Morsette D., Bowcock A. M., Schmutte C., Henriet P. and DeClerck Y. A. (1996) Structure and characterization of the human tissue inhibitor of matrix metalloproteinase-2 gene. J. Biol. Chem. 271, 2 498-2 0.
18. Haorah J., Ramirez S. H., Schall K., Smith D., Pandya R. and Persidsky Y. (2007) Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. J. Neurochem. 101, 66- 76.
19. Hsu H. and Wen M. (2002) Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of inter-leukin-1 gene expression. J. Biol. Chem. 277, 22131-23139.
20. Jian K. and Rosenberg G. A. (200 ) Matrix metalloproteinases and free radicals in cerebral ischemia. Free Rad. Biol Med. 39, 71-80.
21. Kim S. U. and de Vellis J. (2005) Microglia in health and disease. J. Neurosci. Res. 81, 302-313.
22. Kim Y. S. and Joh T. H. (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp. Mol. Med. 38, 333-347.
23. Kim W. K. and Ko K. H. (1998) Potentiation of N-methyl-D-aspartate- mediated neurotoxicity by immunostimulated murine microglia. J. Neurosci. Res. 54, 17-26.
24. Kim S. Y., Jung S. H. and Kim H. S. (2005a) Curcumin is a potent broad spectrum inhibitor of matrix metalloproteinase gene expression in human astroglioma cells. Biochem. Biophys. Res. Commun. 337, 510-516.
25. Kim Y. S., Kim S. S., Cho J. J., Choi D. H., Hwang O., Shin D. H., Chun H. S., Beal M. F. and Joh T. H. (2005b) Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J. Neurosci. 25, 3701-3711.
26. Kim Y. S., Choi D. H., Block M. L. et al. (2007) A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuroal degeneration via microglial activation. FASEB J. 21, 179-187.
27. Lim G. P., Yang F., Chu T. et al (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714.
28. Lim S. Y., Tennant G. M., Kennedy S., Wainwright C. L. and Kane K. A. (2006) Activation of mouse protease-activated receptor-2 induces lymphocyte adhesion and generation of reactive oxygen species. Br. J. Pharmacol. 149, 591-599.
29. Liuzzi G. M., Latronico T., Rossano R., Viggiani S., Fasano A. and Riccio P. (2007) Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells-implications for complementary multiple sclerosis treatment. Neurochem. Res. 32, 2184-2193.
30. Lorenzl S., Calingasan N., Yang L. et al. (2004) Matrix metalloproteinase- 9 is elevated in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced parkinsonism in mice. Neuromuscular Med. 5, 119-132.
31. McGeer P. L., Itagaki S., Boyes B. E. and McGeer E. G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291.
32. Mun-Bryce S., Lukes A., Wallace J., Lukes-Marx M. and Rosenberg G. A. (2002) Stromelysin and gelatinase A are upregulated before TNF-a in LPS-stimulated neuroinflammation. Brain Res. 933, 42-49.
33. Nelson K. K. and Melendez J. A. (2004) Mitochondrial redox control of matrix metalloproteinases. Free Radic. Biol. Med. 37, 768-784.
34. Nguyen H. X., O'Barr T. J. and Anderson A. J. (2007) Polymorpho-nuclear leukocytes promote neurotoxicity through release of matrix metalloproteinases, reactive oxygen species, and TNF-alpha. J. Neurochem. 102, 900-912.
35. Noble L. J., Donovan F., Igarashi T., Goussev S. and Werb Z. (2002) Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J. Neurosci. 22, 7526-7535.
36. Nuttall R. K., Silva C., Hader W., Bar-Or A., Patel K. D., Edwards D. R. and Yong V. W. (2007) Metalloproteinases are enriched in micro-glia compared with leukocytes and they regulate cytokine levels in activated microglia. Glia 55, 516-526.
37. Pahl H. L. (1999) Activators and target genes of Rel/NF-jB transcription factors. Oncogene 18, 6853-6866.
38. Pfeilschifter J., Eberhardt W. and Huwiler A. (2001) Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets. Eur. J. Pharmacol. 429, 279-286.
39. Qin L., Block M. L., Liu Y. et al. (2005) Microglial NADPH oxidase is a novel target for femtomolar neuroprotection against oxidative stress. FASEB J. 19, 550-557.
40. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D. L. and Quigley J. P. (1999) Activation of matrix metallo-proteinase-9 (MMP-9) via a converging plasmin/ stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274, 13066-13076.
41. Rosenberg G. A. (2002) Matrix metalloproteinases in neuroinflammation. Glia 39, 279-291.
42. Rosenberg G. A., Dencoff J. E., Correa Jr N., Reiners M. and Ford C. C. (1996) Effects of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46, 1626-1632.
43. Ryu J., Pyo H., Jou I. and Jo E. (2000) Thrombin induces NO release from cultured rat microglia via protein kinase C, mitogen-activated protein kinase, and NF-kappa B. J. Biol. Chem. 275, 29955-29959.
44. Simard A. R. and Rivest S. (2007) Neuroprotective effects of resident microglia following acute brain injury. J. Comp. Neurol. 504, 716-729.
45. Sternlicht M. D. and Werb Z. (2001) How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell. Dev. Bio. 17, 263-516.
46. Streit W. J., Conde J. R., Fendrick S. E., Flanary B. E. and Mariani C. L. (2005) Role of microglia in the central nervous system's immune response. Neurol Res. 27, 685-691.
47. Suo Z., Wu M., Ameenuddin S., Anderson H. E., Zoloty J. E., Citron. A., Andrade-Gordon P. and Festoff B. W. (2002) Participation f protease-activated receptor-1 in thrombin-induced microglial ctivation. J. Neurochem. 80, 655-666.
48. Suo Z., Wu M., Citron B. A., Gao C. and Festoff B. W. (2003) Persistent protease-activated receptor 4 signaling mediates thrombin-induced microglial activation. J. Biol. Chem. 278, 31177-31183.
49. Tan J., Town T., Crawford F. et al. (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer's disease. Nat. Neurosci. 5, 1288-1293.
50. Wells J. E., Rice T. K., Nuttall R. K., Edwards D. R., Zekki H., Rivest S. and Yong V. W. (2003) An adverse role for matrix metallopro-teinase 12 after spinal cord injury in mice. J. Neurosci. 23, 10107-10115.
51. Woo M. S., Jang P. G., Park J. S., Kim W. K., Joh T. H. and Kim H. S. (2003) Selective modulation of lipopolysaccharide-stimulated cytokine expression and mitogen-activated protein kinase pathways by dibutyryl-cAMP in BV2 microglial cells. Mol. Brain. Res. 113, 86-96.
52. Yin K. J., Cirrito J. R., Yan P. et al. (2006) Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-β peptide catabolism. J. Neurosci. 26, 10939-10948.
53. Yong V. W., Krekoski C. A., Forsyth P. A., Bell R. and Edwards D. R. (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21, 75-80.
54. Yong V. W., Power C., Forsyth P. and Edwards D. R. (2001) Matrix metalloproteinases in biology and pathology of the nervous system. Nat. Rev. Neurosci. 2, 502-511.
55. Yong V. W., Agrawal S. M. and Stirling D. P. (2007) Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics 4, 580-589.